pliaglis Drug Patent Profile
✉ Email this page to a colleague
When do Pliaglis patents expire, and when can generic versions of Pliaglis launch?
Pliaglis is a drug marketed by Crescita Therap and is included in one NDA. There are three patents protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in PLIAGLIS is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.
DrugPatentWatch® Generic Entry Outlook for Pliaglis
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 14, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for pliaglis?
- What are the global sales for pliaglis?
- What is Average Wholesale Price for pliaglis?
Summary for pliaglis
International Patents: | 7 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 10 |
Drug Prices: | Drug price information for pliaglis |
What excipients (inactive ingredients) are in pliaglis? | pliaglis excipients list |
DailyMed Link: | pliaglis at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pliaglis
Generic Entry Date for pliaglis*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for pliaglis
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cutia Therapeutics(Wuxi)Co.,Ltd | Phase 3 |
University of Michigan | Phase 4 |
American Association of Endodontists | Phase 4 |
Pharmacology for pliaglis
Drug Class | Amide Local Anesthetic Antiarrhythmic Ester Local Anesthetic |
Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for pliaglis
pliaglis is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of pliaglis is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for pliaglis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for pliaglis
When does loss-of-exclusivity occur for pliaglis?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11205730
Patent: Solid-forming local anesthetic formulations for pain control
Estimated Expiration: ⤷ Subscribe
Brazil
Patent: 2012017554
Patent: formulações de anestésicas locais formadoras de sólido para controle da dor
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 22220
Patent: FORMULATIONS POUR ANESTHESIE LOCALE SE SOLIDIFIANT POUR LA GESTION DE LA DOULEUR (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL)
Estimated Expiration: ⤷ Subscribe
China
Patent: 2834096
Patent: Solid-forming local anesthetic formulations for pain control
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 23660
Patent: FORMULATIONS POUR ANESTHÉSIE LOCALE SE SOLIDIFIANT POUR LA GESTION DE LA DOULEUR (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL)
Estimated Expiration: ⤷ Subscribe
Mexico
Patent: 12008168
Patent: FORMULACIONES ANESTESICAS LOCALES QUE FORMAN SOLIDOS PARA CONTROL DEL DOLOR. (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL.)
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering pliaglis around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1376043 | ⤷ Subscribe | |
Portugal | 1244401 | ⤷ Subscribe | |
Japan | 2005501014 | ⤷ Subscribe | |
China | 1610540 | ⤷ Subscribe | |
China | 1200017 | ⤷ Subscribe | |
Japan | 2003524508 | ⤷ Subscribe | |
China | 1543342 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Pliaglis Market Analysis and Financial Projection Experimental
More… ↓